miRNA-Based Technologies in Cancer Therapy

The discovery of therapeutic miRNAs is one of the most exciting challenges for pharmaceutical companies. Since the first miRNA was discovered in 1993, our knowledge of miRNA biology has grown considerably. Many studies have demonstrated that miRNA expression is dysregulated in many diseases, making...

Descripción completa

Detalles Bibliográficos
Autores principales: Pagoni, Maria, Cava, Claudia, Sideris, Diamantis C., Avgeris, Margaritis, Zoumpourlis, Vassilios, Michalopoulos, Ioannis, Drakoulis, Nikolaos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10672431/
https://www.ncbi.nlm.nih.gov/pubmed/38003902
http://dx.doi.org/10.3390/jpm13111586
_version_ 1785140389613666304
author Pagoni, Maria
Cava, Claudia
Sideris, Diamantis C.
Avgeris, Margaritis
Zoumpourlis, Vassilios
Michalopoulos, Ioannis
Drakoulis, Nikolaos
author_facet Pagoni, Maria
Cava, Claudia
Sideris, Diamantis C.
Avgeris, Margaritis
Zoumpourlis, Vassilios
Michalopoulos, Ioannis
Drakoulis, Nikolaos
author_sort Pagoni, Maria
collection PubMed
description The discovery of therapeutic miRNAs is one of the most exciting challenges for pharmaceutical companies. Since the first miRNA was discovered in 1993, our knowledge of miRNA biology has grown considerably. Many studies have demonstrated that miRNA expression is dysregulated in many diseases, making them appealing tools for novel therapeutic approaches. This review aims to discuss miRNA biogenesis and function, as well as highlight strategies for delivering miRNA agents, presenting viral, non-viral, and exosomic delivery as therapeutic approaches for different cancer types. We also consider the therapeutic role of microRNA-mediated drug repurposing in cancer therapy.
format Online
Article
Text
id pubmed-10672431
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-106724312023-11-09 miRNA-Based Technologies in Cancer Therapy Pagoni, Maria Cava, Claudia Sideris, Diamantis C. Avgeris, Margaritis Zoumpourlis, Vassilios Michalopoulos, Ioannis Drakoulis, Nikolaos J Pers Med Review The discovery of therapeutic miRNAs is one of the most exciting challenges for pharmaceutical companies. Since the first miRNA was discovered in 1993, our knowledge of miRNA biology has grown considerably. Many studies have demonstrated that miRNA expression is dysregulated in many diseases, making them appealing tools for novel therapeutic approaches. This review aims to discuss miRNA biogenesis and function, as well as highlight strategies for delivering miRNA agents, presenting viral, non-viral, and exosomic delivery as therapeutic approaches for different cancer types. We also consider the therapeutic role of microRNA-mediated drug repurposing in cancer therapy. MDPI 2023-11-09 /pmc/articles/PMC10672431/ /pubmed/38003902 http://dx.doi.org/10.3390/jpm13111586 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Pagoni, Maria
Cava, Claudia
Sideris, Diamantis C.
Avgeris, Margaritis
Zoumpourlis, Vassilios
Michalopoulos, Ioannis
Drakoulis, Nikolaos
miRNA-Based Technologies in Cancer Therapy
title miRNA-Based Technologies in Cancer Therapy
title_full miRNA-Based Technologies in Cancer Therapy
title_fullStr miRNA-Based Technologies in Cancer Therapy
title_full_unstemmed miRNA-Based Technologies in Cancer Therapy
title_short miRNA-Based Technologies in Cancer Therapy
title_sort mirna-based technologies in cancer therapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10672431/
https://www.ncbi.nlm.nih.gov/pubmed/38003902
http://dx.doi.org/10.3390/jpm13111586
work_keys_str_mv AT pagonimaria mirnabasedtechnologiesincancertherapy
AT cavaclaudia mirnabasedtechnologiesincancertherapy
AT siderisdiamantisc mirnabasedtechnologiesincancertherapy
AT avgerismargaritis mirnabasedtechnologiesincancertherapy
AT zoumpourlisvassilios mirnabasedtechnologiesincancertherapy
AT michalopoulosioannis mirnabasedtechnologiesincancertherapy
AT drakoulisnikolaos mirnabasedtechnologiesincancertherapy

Ejemplares similares